Search clinical trials for: Gastroesophageal Junction Neoplasms

Total 109012 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8 | Pathologic... and other conditions

United States
Merus N.V.
Chiltern International Inc.; Q2 Solutions; Oncology Therapeutic Development (OTD) and other collaborators

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Gastric Cancer | Colorectal Cancer | NSCLC | Head and Neck Squamous Cell Carcinoma | HNSCC | Advanced/Metastatic Solid Tumors | Gastroesophageal-junction Cancer

United States, Spain, Belgium, France, Netherlands, United Kingdom
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Japan, Italy, Korea, Republic of, Taiwan, France
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG

Recruiting

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Germany, Switzerland
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Recruiting

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (ARMANI)

Stomach Neoplasms

Italy
Asan Medical Center
Ulsan University Hospital; Seoul National University Bundang Hospital; Gachon... and other collaborators

Recruiting

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

Gastric Cancer

Korea, Republic of
Dr. Gordon Buduhan
University of Toronto; London Health Sciences Centre; CancerCare Manitoba

Recruiting

Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (POWERRANGER)

Esophageal Cancer | Adenocarcinoma, Esophageal | Adenocarcinoma, Gastroesophageal Junction

Canada
University of Pittsburgh
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Esophageal Cancer Risk Registry

Esophageal Cancer | Esophageal Diseases | Hiatal Hernia | Esophageal Achalasia | Gastroesophageal Reflux Disease (GERD)

United States
AHS Cancer Control Alberta

Completed

iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Carcinoma

Canada
Astellas Pharma Inc

Completed

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastro-esophageal Junction (GEJ) Cancer

Japan
Arcus Biosciences, Inc.
Gilead Sciences; Taiho Pharmaceutical Co., Ltd.

Active, not recruiting

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

Advanced Upper Gastrointestinal Tract Adenocarcinoma

Korea, Republic of, Spain, United States, France, United Kingdom, China, Israel, Poland, Japan, Hungary, Australia, Malaysia, Serbia, Thailand, Canada, Lithuania, Italy, Philippines, Portugal, Brazil, Argentina, Romania, Peru, Hong Kong, Chi... and more
Shattuck Labs, Inc.

Completed

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Melanoma | Renal Cell Carcinoma | Hodgkin Lymphoma | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Diffuse Large B Cell Lymphoma | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Squamous Cell Carcinoma of the Skin | Squamous Cell Carcinoma... and other conditions

United States, Canada, Belgium, Spain
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Stomach Neoplasms

China, Japan, Poland, Turkey, Brazil, United States, Argentina, Australia, Canada, Chile, Colombia, Costa Rica, Czechia, Denmark, France, Germany, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, New Zealand and more
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

China
National Cancer Institute (NCI)

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic... and other conditions

United States
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)

Melanoma | Lymphoma, Non-Hodgkin | Cervical Cancer | Multiple Myeloma | Gastric Cancer | Esophageal Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma | Non Small Cell Lung Cancer (NSCLC) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, Spain, Poland
Jazz Pharmaceuticals

Active, not recruiting

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

United States, Korea, Republic of, Chile, Canada
Triumvira Immunologics, Inc.
Merck Sharp & Dohme LLC

Terminated

TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

HER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Gastric Cancer | Gastric Adenocarcinoma | Esophagogastric Junction

United States
Shadia Jalal, MD
GlaxoSmithKline; Indiana University School of Medicine

Terminated

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Adenocarcinoma | Gastric Cancer | Esophageal Cancer

United States
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC; Surface Oncology

Completed

Study of SRF617 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States, Canada
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb

Active, not recruiting

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

HER2-positive Breast Cancer | HER2-positive Colorectal Cancer | HER2-positive Solid Tumors | HER2-positive Gastroesophageal Cancer | HER2-positive Endometrial Cancer

France, United States, Spain, Korea, Republic of, Italy
Pfizer

Active, not recruiting

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Breast Neoplasms | Colorectal Cancer | Metastatic HER2+ Advanced Breast Cancer | Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

China
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
BeiGene

Active, not recruiting

Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Cancer

China, Taiwan, Korea, Republic of
University of Chicago

Terminated

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Gastric Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage 0 Gastric... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Peritoneal Carcinomatosis | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
MacroGenics
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)

Gastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric Cancer

Korea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
Nanfang Hospital, Southern Medical University

Completed

JNT Versus TNT to Guided OGT-overlap Oesophagojejunostomy

Gastric/Gastroesophageal Junction (g/Gej) Cancer

China
BeiGene

Active, not recruiting

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Gastric, or Gastroesophageal Junction Adenocarcinoma

United States, China, Spain, Korea, Republic of, Poland, Russian Federation, Taiwan, France, Turkey, Japan, Italy, United Kingdom, Puerto Rico
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Gastric Cancer | Gastroesophageal Junction Cancer

China
AstraZeneca
Daiichi Sankyo Co., Ltd.

Completed

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Apexigen America, Inc.

Completed

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Esophageal Cancer | GastroEsophageal Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Brain and other conditions

United States
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Northern Jiangsu People's Hospital

Completed

A 3-Arm Study Comparing the Efficacy of Anti-Reflux Reconstruction Protocols After Laparoscopic Proximal Gastrectomy

Anti-Reflux Alimentary Reconstruction | Laparoscopic Proximal Gastrectomy | Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction

China

Search clinical trials for: Gastroesophageal Junction Neoplasms

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations